{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:27:12Z","timestamp":1791919632537,"version":"4.3.4"},"reference-count":119,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T00:00:00Z","timestamp":1712793600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Cancer persists as a global challenge necessitating continual innovation in treatment strategies. Despite significant advancements in comprehending the disease, cancer remains a leading cause of mortality worldwide, exerting substantial economic burdens on healthcare systems and societies. The emergence of drug resistance further complicates therapeutic efficacy, underscoring the urgent need for alternative approaches. Drug repurposing, characterized by the utilization of existing drugs for novel clinical applications, emerges as a promising avenue for addressing these challenges. Repurposed drugs, comprising FDA-approved (in other disease indications), generic, off-patent, and failed medications, offer distinct advantages including established safety profiles, cost-effectiveness, and expedited development timelines compared to novel drug discovery processes. Various methodologies, such as knowledge-based analyses, drug-centric strategies, and computational approaches, play pivotal roles in identifying potential candidates for repurposing. However, despite the promise of repurposed drugs, drug repositioning confronts formidable obstacles. Patenting issues, financial constraints associated with conducting extensive clinical trials, and the necessity for combination therapies to overcome the limitations of monotherapy pose significant challenges. This review provides an in-depth exploration of drug repurposing, covering a diverse array of approaches including experimental, re-engineering protein, nanotechnology, and computational methods. Each of these avenues presents distinct opportunities and obstacles in the pursuit of identifying novel clinical uses for established drugs. By examining the multifaceted landscape of drug repurposing, this review aims to offer comprehensive insights into its potential to transform cancer therapeutics.<\/jats:p>","DOI":"10.3390\/cancers16081463","type":"journal-article","created":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T07:09:28Z","timestamp":1712819368000},"page":"1463","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Revitalizing Cancer Treatment: Exploring the Role of Drug Repurposing"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2448-1681","authenticated-orcid":false,"given":"RamaRao","family":"Malla","sequence":"first","affiliation":[{"name":"Cancer Biology Laboratory, Department of Biochemistry and Bioinformatics, GITAM School of Science, GITAM (Deemed to be University), Visakhapatnam 530045, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sathiyapriya","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, ACS Medical College and Hospital, Chennai 600007, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sree","family":"Makena","sequence":"additional","affiliation":[{"name":"Maharajah\u2019s Institute of Medical Sciences and Hospital, Vizianagaram 535217, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Kapoor","sequence":"additional","affiliation":[{"name":"Department of Genetics, University of Alabama, Birmingham, AL 35233, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4699-9609","authenticated-orcid":false,"given":"Deepak","family":"Verma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD 21231, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alluri Ashok","family":"Raju","sequence":"additional","affiliation":[{"name":"Medicover Hospitals, Visakhapatnam 530022, Andhra Pradesh, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9549-1954","authenticated-orcid":false,"given":"Manikantha","family":"Dunna","sequence":"additional","affiliation":[{"name":"Center for Biotechnology, Jawaharlal Nehru Technological University, Hyderabad 500085, Telangana, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3820-2148","authenticated-orcid":false,"given":"Nethaji","family":"Muniraj","sequence":"additional","affiliation":[{"name":"Center for Cancer and Immunology Research, Children\u2019s National Hospital, 111, Michigan Ave NW, Washington, DC 20010, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,4,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/s43018-019-0018-6","article-title":"Discovering the anticancer potential of non-oncology drugs by systematic viability profiling","volume":"1","author":"Corsello","year":"2020","journal-title":"Nat. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3322\/caac.21652","article-title":"Blueprint for cancer research: Critical gaps and opportunities","volume":"71","author":"Elmore","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1038\/s41563-019-0338-z","article-title":"Exploiting machine learning for end-to-end drug discovery and development","volume":"18","author":"Ekins","year":"2019","journal-title":"Nat. Mater."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrd3461","article-title":"Mining for therapeutic gold","volume":"10","author":"Collins","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s12094-014-1162-1","article-title":"Cancer cell resistance mechanisms: A mini review","volume":"16","year":"2014","journal-title":"Clin. Transl. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/B978-0-12-386009-5.00004-7","article-title":"The future of drug repositioning: Old drugs, new opportunities","volume":"Volume 46","author":"Doan","year":"2011","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/nrd3078","article-title":"How to improve R&D productivity: The pharmaceutical industry\u2019s grand challenge","volume":"9","author":"Paul","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1038\/534314a","article-title":"New tricks for old drugs","volume":"534","author":"Nosengo","year":"2016","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/s41416-023-02502-9","article-title":"Unlocking hidden potential: Advancements, approaches, and obstacles in repurposing drugs for cancer therapy","volume":"130","author":"Weth","year":"2023","journal-title":"Br. J. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1177\/1740774515625964","article-title":"Key cost drivers of pharmaceutical clinical trials in the United States","volume":"13","author":"Sertkaya","year":"2016","journal-title":"Clin. Trials"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug repurposing: Progress, challenges and recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug repurposing: An effective tool in modern drug discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorganic Chem."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"620","DOI":"10.3389\/fphar.2017.00620","article-title":"Tamoxifen from failed contraceptive pill to best-selling breast cancer medicine: A case-study in pharmaceutical innovation","volume":"8","author":"Quirke","year":"2017","journal-title":"Front. Pharmacol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.semcancer.2019.09.023","article-title":"Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets","volume":"Volume 68","author":"Mottini","year":"2021","journal-title":"Seminars in Cancer Biology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/med.21764","article-title":"Artificial intelligence and machine learning-aided drug discovery in central nervous system diseases: State-of-the-arts and future directions","volume":"41","author":"Vatansever","year":"2021","journal-title":"Med. Res. Rev."},{"key":"ref_16","first-page":"1287","article-title":"Repositioning Generic Drugs: Empirical Findings and Policy Implications","volume":"53","author":"Liddicoat","year":"2022","journal-title":"IIC Int. Rev. Intellect. Prop. Compet. Law"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22813","DOI":"10.3402\/jmahp.v2.22813","article-title":"Drug reformulations and repositioning in the pharmaceutical industry and their impact on market access: Regulatory implications","volume":"2","author":"Murteira","year":"2014","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"114239","DOI":"10.1016\/j.ejmech.2022.114239","article-title":"Drug repositioning: Progress and challenges in drug discovery for various diseases","volume":"234","author":"Hua","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Zannetti, A. (2023). Breast Cancer: From Pathophysiology to Novel Therapeutic Approaches 2.0. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032542"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1016\/j.cell.2023.01.040","article-title":"Deciphering breast cancer: From biology to the clinic","volume":"186","author":"Nolan","year":"2023","journal-title":"Cell"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"102109","DOI":"10.1016\/j.ceca.2019.102109","article-title":"Subtype specific targeting of calcium signaling in breast cancer","volume":"85","author":"Makena","year":"2020","journal-title":"Cell Calcium"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Hijazi, M.A., Gessner, A., and El-Najjar, N. (2023). Repurposing of Chronically Used Drugs in Cancer Therapy: A Chance to Grasp. Cancers, 15.","DOI":"10.3390\/cancers15123199"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Gales, L., Forsea, L., Mitrea, D., Stefanica, I., Stanculescu, I., Mitrica, R., Georgescu, M., Trifanescu, O., Anghel, R., and Serbanescu, L. (2022). Antidiabetics, Anthelmintics, Statins, and Beta-Blockers as Co-Adjuvant Drugs in Cancer Therapy. Medicina, 58.","DOI":"10.3390\/medicina58091239"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.bbrc.2014.03.047","article-title":"Inhibitory effect of Disulfiram\/copper complex on non-small cell lung cancer cells","volume":"446","author":"Duan","year":"2014","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.molonc.2015.02.007","article-title":"Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer","volume":"9","author":"Allensworth","year":"2015","journal-title":"Mol. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10441","DOI":"10.2147\/OTT.S271532","article-title":"The Evolving Role of Disulfiram in Radiobiology and the Treatment of Breast Cancer","volume":"13","author":"Wang","year":"2020","journal-title":"Onco Targets Ther."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/CEJ.0b013e3283647466","article-title":"Use of disulfiram and risk of cancer: A population-based case-control study","volume":"23","author":"Askgaard","year":"2014","journal-title":"Eur. J. Cancer Prev."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"40907","DOI":"10.18632\/oncotarget.5723","article-title":"Disulfiram inhibits TGF-\u03b2-induced epithelial-mesenchymal transition and stem-like features in breast cancer via ERK\/NF-\u03baB\/Snail pathway","volume":"6","author":"Han","year":"2015","journal-title":"Oncotarget"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"3996","DOI":"10.1158\/0008-5472.CAN-09-3752","article-title":"Disulfiram treatment facilitates phosphoinositide 3-kinase inhibition in human breast cancer cells in vitro and in vivo","volume":"70","author":"Zhang","year":"2010","journal-title":"Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1007\/s43440-020-00122-1","article-title":"Disulfiram potentiates docetaxel cytotoxicity in breast cancer cells through enhanced ROS and autophagy","volume":"72","author":"Swetha","year":"2020","journal-title":"Pharmacol. Rep. PR"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.bcp.2014.12.014","article-title":"Disulfiram-induced cytotoxicity and endo-lysosomal sequestration of zinc in breast cancer cells","volume":"93","author":"Wiggins","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Lafi, Z., Alshaer, W., Gharaibeh, L., Alqudah, D.A., AlQuaissi, B., Bashaireh, B., and Ibrahim, A.A. (2023). Synergistic combination of doxorubicin with hydralazine, and disulfiram against MCF-7 breast cancer cell line. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0291981"},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Makena, M.R., Ranjan, A., Thirumala, V., and Reddy, A.P. (2020). Cancer stem cells: Road to therapeutic resistance and strategies to overcome resistance. Biochim. Biophys. Acta (BBA)-Mol. Basis Dis., 1866.","DOI":"10.1016\/j.bbadis.2018.11.015"},{"key":"ref_34","first-page":"pgac013","article-title":"The endosomal pH regulator NHE9 is a driver of stemness in glioblastoma","volume":"1","author":"Ko","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA Nexus"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/bjc.2011.126","article-title":"Disulfiram modulated ROS-MAPK and NF\u03baB pathways and targeted breast cancer cells with cancer stem cell-like properties","volume":"104","author":"Yip","year":"2011","journal-title":"Br. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Chu, M., An, X., Zhang, D., Li, Q., Dai, X., Yu, H., and Li, Z. (2022). Combination of the 6-thioguanine and disulfiram\/Cu synergistically inhibits proliferation of triple-negative breast cancer cells by enhancing DNA damage and disrupting DNA damage checkpoint. Biochim. Biophys. Acta. Mol. Cell Res., 1869.","DOI":"10.1016\/j.bbamcr.2021.119169"},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Yang, Z., Guo, F., Albers, A.E., Sehouli, J., and Kaufmann, A.M. (2019). Disulfiram modulates ROS accumulation and overcomes synergistically cisplatin resistance in breast cancer cell lines. Biomed. Pharmacother., 113.","DOI":"10.1016\/j.biopha.2019.108727"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.bbrc.2017.03.164","article-title":"Disulfiram suppresses cancer stem-like properties and STAT3 signaling in triple-negative breast cancer cells","volume":"486","author":"Kim","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.05.026","article-title":"Disulfiram targets cancer stem-like properties and the HER2\/Akt signaling pathway in HER2-positive breast cancer","volume":"379","author":"Kim","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Fasehee, H., Dinarvand, R., Ghavamzadeh, A., Esfandyari-Manesh, M., Moradian, H., Faghihi, S., and Ghaffari, S.H. (2016). Delivery of disulfiram into breast cancer cells using folate-receptor-targeted PLGA-PEG nanoparticles: In vitro and in vivo investigations. J. Nanobiotechnol., 14.","DOI":"10.1186\/s12951-016-0183-z"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"7471","DOI":"10.18632\/oncotarget.2166","article-title":"Liposome encapsulated Disulfiram inhibits NF\u03baB pathway and targets breast cancer stem cells in vitro and in vivo","volume":"5","author":"Liu","year":"2014","journal-title":"Oncotarget"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"5919","DOI":"10.1158\/0008-5472.CAN-21-1337","article-title":"ALDH1A1 Activity in Tumor-Initiating Cells Remodels Myeloid-Derived Suppressor Cells to Promote Breast Cancer Progression","volume":"81","author":"Liu","year":"2021","journal-title":"Cancer Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1080\/17425247.2023.2237888","article-title":"Enzyme\/pH dual stimuli-responsive nanoplatform co-deliver disulfiram and doxorubicin for effective treatment of breast cancer lung metastasis","volume":"20","author":"Xiao","year":"2023","journal-title":"Expert Opin. Drug Deliv."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Solak, K., Mavi, A., and Y\u0131lmaz, B. (2021). Disulfiram-loaded functionalized magnetic nanoparticles combined with copper and sodium nitroprusside in breast cancer cells. Mater. Sci. Eng. C Mater Biol. Appl., 119.","DOI":"10.1016\/j.msec.2020.111452"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"119191","DOI":"10.1016\/j.ijpharm.2020.119191","article-title":"Coencapsulation of disulfiram and doxorubicin in liposomes strongly reverses multidrug resistance in breast cancer cells","volume":"580","author":"Rolle","year":"2020","journal-title":"Int. J. Pharm."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Chu, M., An, X., Fu, C., Yu, H., Zhang, D., Li, Q., Man, X., Dai, X., and Li, Z. (2023). Disulfiram\/Copper Induce Ferroptosis in Triple-Negative Breast Cancer Cell Line MDA-MB-231. Front. Biosci., 28.","DOI":"10.31083\/j.fbl2808186"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.canlet.2016.11.022","article-title":"Disulfiram induces anoikis and suppresses lung colonization in triple-negative breast cancer via calpain activation","volume":"386","author":"Kim","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.ijbiomac.2022.01.145","article-title":"Fabrication, characterization and in vitro evaluation of disulfiram-loaded cellulose acetate\/poly(ethylene oxide) nanofiber scaffold for breast and colon cancer cell lines treatment","volume":"204","year":"2022","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"5727","DOI":"10.1038\/s41467-023-41282-x","article-title":"Stressed target cancer cells drive nongenetic reprogramming of CAR T cells and solid tumor microenvironment","volume":"14","author":"Wang","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.2174\/2589977513666210127094222","article-title":"Low Doses Naltrexone: The Potential Benefit Effects for its Use in Patients with Cancer","volume":"13","author":"Couto","year":"2021","journal-title":"Curr Drug Res. Rev."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1007\/s10637-022-01317-4","article-title":"An open label phase II study of safety and clinical activity of naltrexone for treatment of hormone refractory metastatic breast cancer","volume":"41","author":"Vijayakumar","year":"2023","journal-title":"Investig. New Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Murugan, S., Rousseau, B., and Sarkar, D.K. (2021). Beta 2 Adrenergic Receptor Antagonist Propranolol and Opioidergic Receptor Antagonist Naltrexone Produce Synergistic Effects on Breast Cancer Growth Prevention by Acting on Cancer Cells and Immune Environment in a Preclinical Model of Breast Cancer. Cancers, 13.","DOI":"10.3390\/cancers13194858"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"189","DOI":"10.3347\/kjp.2021.59.3.189","article-title":"Albendazole and Mebendazole as Anti-Parasitic and Anti-Cancer Agents: An Update","volume":"59","author":"Chai","year":"2021","journal-title":"Korean J. Parasitol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2945","DOI":"10.1007\/s00432-021-03698-0","article-title":"Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death","volume":"147","author":"Petersen","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"73","DOI":"10.2174\/2589977512999200821170221","article-title":"Repurposing of Benzimidazole Scaffolds for HER2 Positive Breast Cancer Therapy: An In-Silico Approach","volume":"13","author":"Jubie","year":"2021","journal-title":"Curr Drug Res Rev"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Racoviceanu, R., Trandafirescu, C., Voicu, M., Ghiulai, R., Borcan, F., Dehelean, C., Watz, C., Aigner, Z., Ambrus, R., and Coricovac, D.E. (2020). Solid Polymeric Nanoparticles of Albendazole: Synthesis, Physico-Chemical Characterization and Biological Activity. Molecules, 25.","DOI":"10.3390\/molecules25215130"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12282-019-01027-5","article-title":"(18)F-FDG PET imaging for monitoring the early anti-tumor effect of albendazole on triple-negative breast cancer","volume":"27","author":"Liu","year":"2020","journal-title":"Breast Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"3734","DOI":"10.1208\/s12249-018-1169-y","article-title":"Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer","volume":"19","author":"Priotti","year":"2018","journal-title":"AAPS PharmSciTech"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13058-022-01591-3","article-title":"Mebendazole prevents distant organ metastases in part by decreasing ITG\u03b24 expression and cancer stemness","volume":"24","author":"Joe","year":"2022","journal-title":"Breast Cancer Res. BCR"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Joe, N.S., Wang, Y., Oza, H.H., Godet, I., Milki, N., Riggins, G.J., and Gilkes, D.M. (2023). Mebendazole Treatment Disrupts the Transcriptional Activity of Hypoxia-Inducible Factors 1 and 2 in Breast Cancer Cells. Cancers, 15.","DOI":"10.3390\/cancers15041330"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Kefayat, A., Hosseini, M., Ghahremani, F., Jolfaie, N.A., and Rafienia, M. (2022). Biodegradable and biocompatible subcutaneous implants consisted of pH-sensitive mebendazole-loaded\/folic acid-targeted chitosan nanoparticles for murine triple-negative breast cancer treatment. J. Nanobiotechnol., 20.","DOI":"10.1186\/s12951-022-01380-2"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1021\/acsomega.1c05519","article-title":"In Silico and In Vitro Studies for Benzimidazole Anthelmintics Repurposing as VEGFR-2 Antagonists: Novel Mebendazole-Loaded Mixed Micelles with Enhanced Dissolution and Anticancer Activity","volume":"7","author":"Elmaaty","year":"2022","journal-title":"ACS Omega"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ijrobp.2018.08.046","article-title":"Mebendazole Potentiates Radiation Therapy in Triple-Negative Breast Cancer","volume":"103","author":"Zhang","year":"2019","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Choi, H.S., Ko, Y.S., Jin, H., Kang, K.M., Ha, I.B., Jeong, H., Song, H.N., Kim, H.J., and Jeong, B.K. (2021). Anticancer Effect of Benzimidazole Derivatives, Especially Mebendazole, on Triple-Negative Breast Cancer (TNBC) and Radiotherapy-Resistant TNBC In Vivo and In Vitro. Molecules, 26.","DOI":"10.3390\/molecules26175118"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"Choi, H.S., Ko, Y.S., Jin, H., Kang, K.M., Ha, I.B., Jeong, H., Lee, J.H., Jeong, B.K., and Kim, H.J. (2022). Mebendazole Increases Anticancer Activity of Radiotherapy in Radiotherapy-Resistant Triple-Negative Breast Cancer Cells by Enhancing Natural Killer Cell-Mediated Cytotoxicity. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms232415493"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1038\/s41419-022-04823-8","article-title":"Flubendazole induces mitochondrial dysfunction and DRP1-mediated mitophagy by targeting EVA1A in breast cancer","volume":"13","author":"Zhen","year":"2022","journal-title":"Cell Death Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"8080","DOI":"10.7150\/thno.43473","article-title":"Flubendazole elicits anti-cancer effects via targeting EVA1A-modulated autophagy and apoptosis in Triple-negative Breast Cancer","volume":"10","author":"Zhen","year":"2020","journal-title":"Theranostics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1039\/C5MB00466G","article-title":"Systems biology-based discovery of a potential Atg4B agonist (Flubendazole) that induces autophagy in breast cancer","volume":"11","author":"Zhang","year":"2015","journal-title":"Mol. Biosyst."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"6326","DOI":"10.18632\/oncotarget.3436","article-title":"Flubendazole, FDA-approved anthelmintic, targets breast cancer stem-like cells","volume":"6","author":"Hou","year":"2015","journal-title":"Oncotarget"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.canlet.2017.10.020","article-title":"Flubendazole overcomes trastuzumab resistance by targeting cancer stem-like properties and HER2 signaling in HER2-positive breast cancer","volume":"412","author":"Kim","year":"2018","journal-title":"Cancer Lett."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1002\/ijc.31585","article-title":"Flubendazole elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition","volume":"143","author":"Oh","year":"2018","journal-title":"Int J Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Zhou, Y., Liao, M., Li, Z., Ye, J., Wu, L., Mou, Y., Fu, L., and Zhen, Y. (2023). Flubendazole Enhances the Inhibitory Effect of Paclitaxel via HIF1\u03b1\/PI3K\/AKT Signaling Pathways in Breast Cancer. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms242015121"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Gatla, H.R., Muniraj, N., Thevkar, P., Yavvari, S., Sukhavasi, S., and Makena, M.R. (2019). Regulation of chemokines and cytokines by histone deacetylases and an update on histone decetylase inhibitors in human diseases. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20051110"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"7667","DOI":"10.1007\/s11033-023-08568-1","article-title":"The evidence for repurposing anti-epileptic drugs to target cancer","volume":"50","author":"Aroosa","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Caponigro, F., Di Gennaro, E., Ionna, F., Longo, F., Aversa, C., Pavone, E., Maglione, M.G., Di Marzo, M., Muto, P., and Cavalcanti, E. (2016). Phase II clinical study of valproic acid plus cisplatin and cetuximab in recurrent and\/or metastatic squamous cell carcinoma of Head and Neck-V-CHANCE trial. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2957-y"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Wawruszak, A., Halasa, M., Okon, E., Kukula-Koch, W., and Stepulak, A. (2021). Valproic Acid and Breast Cancer: State of the Art in 2021. Cancers, 13.","DOI":"10.3390\/cancers13143409"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"9636897211027524","DOI":"10.1177\/09636897211027524","article-title":"Valproic acid Suppresses Breast Cancer Cell Growth Through Triggering Pyruvate Kinase M2 Isoform Mediated Warburg Effect","volume":"30","author":"Li","year":"2021","journal-title":"Cell Transpl."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1186\/s12967-023-04015-8","article-title":"Valproic acid inhibits cell growth in both MCF-7 and MDA-MB231 cells by triggering different responses in a cell type-specific manner","volume":"21","author":"Giordano","year":"2023","journal-title":"J. Transl. Med."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"119027","DOI":"10.1016\/j.lfs.2021.119027","article-title":"Apoptotic effects of valproic acid on miR-34a, miR-520h and HDAC1 gene in breast cancer","volume":"269","author":"Injinari","year":"2021","journal-title":"Life Sci."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"6752","DOI":"10.1007\/s12010-023-04395-z","article-title":"The Effect of Berberine Follow by Blue Light Irradiation and Valproic Acid on the Growth Inhibition of MDA-MB-231 Breast Cancer Cells","volume":"195","author":"Meschi","year":"2023","journal-title":"Appl. Biochem. Biotechnol."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Granit, A., Mishra, K., Barasch, D., Peretz-Yablonsky, T., Eyal, S., and Kakhlon, O. (2022). Metabolomic profiling of triple negative breast cancer cells suggests that valproic acid can enhance the anticancer effect of cisplatin. Front. Cell Dev. Biol., 10.","DOI":"10.3389\/fcell.2022.1014798"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Granit Mizrahi, A., Gugenheim, A., Hamad, H., Hamed, R., Tetro, N., Maimon, O., Khutsurauli, S., Nechushtan, H., Nisman, B., and Duran, D. (2023). Valproic acid reprograms the metabolic aberration of cisplatin treatment via ALDH modulation in triple-negative breast cancer cells. Front. Cell Dev. Biol., 11.","DOI":"10.3389\/fcell.2023.1217149"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1139\/cjpp-2021-0799","article-title":"Enhanced antitumor activity of combined methotrexate and histone deacetylase inhibitor valproic acid on mammary cancer in vitro and in vivo","volume":"100","author":"Badary","year":"2022","journal-title":"Can. J. Physiol. Pharmacol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e000195","DOI":"10.1136\/jitc-2019-000195","article-title":"Histone deacetylase inhibitors valproic acid and vorinostat enhance trastuzumab-mediated antibody-dependent cell-mediated phagocytosis","volume":"8","author":"Laengle","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"681278","DOI":"10.3389\/fonc.2021.681278","article-title":"Valproic Acid Regulates HR and Cell Cycle Through MUS81-pRPA2 Pathway in Response to Hydroxyurea","volume":"11","author":"Su","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_86","first-page":"955","article-title":"Valproic acid triggers radiation-induced abscopal effect by modulating the unirradiated tumor immune microenvironment in a rat model of breast cancer","volume":"62","author":"Jin","year":"2021","journal-title":"J. Radiat. Res."},{"key":"ref_87","first-page":"41","article-title":"Re-engineering proteins to develop novel immunotherapies","volume":"28","author":"Rege","year":"2023","journal-title":"Eur. Pharm. Rev."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"5451","DOI":"10.4049\/jimmunol.1490019","article-title":"IL-2: The first effective immunotherapy for human cancer","volume":"192","author":"Rosenberg","year":"2014","journal-title":"J. Immunol."},{"key":"ref_89","doi-asserted-by":"crossref","unstructured":"Ko, B., Takebe, N., Andrews, O., Makena, M.R., and Chen, A.P. (2023). Rethinking Oncologic Treatment Strategies with Interleukin-2. Cells, 12.","DOI":"10.3390\/cells12091316"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1200\/JCO.2022.40.16_suppl.2500","article-title":"Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors: ARTISTRY-1","volume":"40","author":"Vaishampayan","year":"2022","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Pramanik, K.C., Makena, M.R., Bhowmick, K., and Pandey, M.K. (2018). Advancement of NF-\u03baB signaling pathway: A novel target in pancreatic cancer. Int. J. Mol. Sci., 19.","DOI":"10.3390\/ijms19123890"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Ram Makena, M., Gatla, H., Verlekar, D., Sukhavasi, S., Pandey, M.K., and Pramanik, K.C. (2019). Wnt\/\u03b2-catenin signaling: The culprit in pancreatic carcinogenesis and therapeutic resistance. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20174242"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1111\/cas.15377","article-title":"Liposomal irinotecan (Onivyde): Exemplifying the benefits of nanotherapeutic drugs","volume":"113","author":"Milano","year":"2022","journal-title":"Cancer Sci."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1158\/1078-0432.CCR-14-1882","article-title":"Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing\u2019s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression","volume":"21","author":"Kang","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","article-title":"Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): A global, randomised, open-label, phase 3 trial","volume":"387","author":"Li","year":"2016","journal-title":"Lancet"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1250136","DOI":"10.3389\/fonc.2023.1250136","article-title":"Clinical outcomes of liposomal irinotecan in advanced pancreatic adenocarcinoma patients previously treated with conventional irinotecan-based chemotherapy: A real-world study","volume":"13","author":"Gupta","year":"2023","journal-title":"Front. Oncol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"LBA661","DOI":"10.1200\/JCO.2023.41.4_suppl.LBA661","article-title":"NAPOLI-3: A randomized, open-label phase 3 study of liposomal irinotecan+ 5-fluorouracil\/leucovorin+ oxaliplatin (NALIRIFOX) versus nab-paclitaxel+ gemcitabine in treatment-na\u00efve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)","volume":"41","author":"Wainberg","year":"2023","journal-title":"Am. Soc. Clin. Oncol."},{"key":"ref_98","unstructured":"Liu, A. (2024). With FDA Nod for Onivyde Combo, Ipsen Ends 10-Year Drought in Newly Diagnosed Pancreatic Cancer, FIERCE PHARMA. Available online: https:\/\/www.fiercepharma.com\/pharma\/ipsen-ends-10-year-drought-fda-nod-onivyde-combo-newly-diagnosed-pancreatic-cancer."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/s41576-021-00387-z","article-title":"Advancing the use of genome-wide association studies for drug repurposing","volume":"22","author":"Reay","year":"2021","journal-title":"Nat. Rev. Genet."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3476","DOI":"10.1038\/s41467-019-10744-6","article-title":"A genome-wide positioning systems network algorithm for in silico drug repurposing","volume":"10","author":"Cheng","year":"2019","journal-title":"Nat. Commun."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"7735","DOI":"10.1080\/07391102.2022.2124453","article-title":"Comprehensive molecular docking and dynamic simulations for drug repurposing of clinical drugs against multiple cancer kinase targets","volume":"41","author":"Shaikh","year":"2023","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1007\/s11030-022-10523-4","article-title":"Docking covalent targets for drug discovery: Stimulating the computer-aided drug design community of possible pitfalls and erroneous practices","volume":"27","author":"Oyedele","year":"2023","journal-title":"Mol. Divers."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"521","DOI":"10.2174\/138620711795767802","article-title":"The design and application of target-focused compound libraries","volume":"14","year":"2011","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1038\/s41401-022-00996-2","article-title":"DrugRep: An automatic virtual screening server for drug repurposing","volume":"44","author":"Gan","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"He, H., Duo, H., Hao, Y., Zhang, X., Zhou, X., Zeng, Y., Li, Y., and Li, B. (2023). Computational drug repurposing by exploiting large-scale gene expression data: Strategy, methods and applications. Comput. Biol. Med., 155.","DOI":"10.1016\/j.compbiomed.2023.106671"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.drudis.2012.07.014","article-title":"Transcriptional data: A new gateway to drug repositioning?","volume":"18","author":"Iorio","year":"2013","journal-title":"Drug Discov. Today"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s12943-018-0782-4","article-title":"Mechanisms of receptor tyrosine kinase activation in cancer","volume":"17","author":"Du","year":"2018","journal-title":"Mol. Cancer"},{"key":"ref_108","first-page":"19","article-title":"Update on the treatment of gastrointestinal stromal tumors (GISTs): Role of imatinib","volume":"4","author":"Quek","year":"2010","journal-title":"Biol. Targets Ther."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1582-4934.2009.00983.x","article-title":"Imatinib treatment for gastrointestinal stromal tumour (GIST)","volume":"14","author":"Lopes","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_110","first-page":"e44359","article-title":"Artificial Intelligence and Machine Learning in Pharmacological Research: Bridging the Gap Between Data and Drug Discovery","volume":"15","author":"Singh","year":"2023","journal-title":"Cureus"},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Taye, M.M. (2023). Understanding of Machine Learning with Deep Learning: Architectures, Workflow, Applications and Future Directions. Computers, 12.","DOI":"10.3390\/computers12050091"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1208\/s12248-021-00644-3","article-title":"Machine learning and artificial intelligence in pharmaceutical research and development: A review","volume":"24","author":"Kolluri","year":"2022","journal-title":"AAPS J."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1080\/17460441.2021.1883585","article-title":"Artificial intelligence, machine learning, and drug repurposing in cancer","volume":"16","author":"Tanoli","year":"2021","journal-title":"Expert Opin. Drug Discov."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Ahmed, F., Soomro, A.M., Salih, A.R.C., Samantasinghar, A., Asif, A., Kang, I.S., and Choi, K.H. (2022). A comprehensive review of artificial intelligence and network based approaches to drug repurposing in COVID-19. Biomed. Pharmacother., 153.","DOI":"10.1016\/j.biopha.2022.113350"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"103730","DOI":"10.1016\/j.critrevonc.2022.103730","article-title":"Drug repositioning for cancer in the era of AI, big omics, and real-world data","volume":"175","author":"Wieder","year":"2022","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1158\/2159-8290.CD-21-0090","article-title":"Artificial intelligence in cancer research and precision medicine","volume":"11","author":"Bhinder","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"e2100109","DOI":"10.1200\/CCI.21.00109","article-title":"Natural language processing\u2013assisted literature retrieval and analysis for combination therapy in cancer","volume":"6","author":"Zeng","year":"2022","journal-title":"JCO Clin. Cancer Inform."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41408-023-00798-7","article-title":"Artificial intelligence-enabled screening strategy for drug repurposing in monoclonal gammopathy of undetermined significance","volume":"13","author":"Ryu","year":"2023","journal-title":"Blood Cancer J."},{"key":"ref_119","doi-asserted-by":"crossref","unstructured":"Mayers, M., Li, T.S., Queralt-Rosinach, N., and Su, A.I. (2019). Time-resolved evaluation of compound repositioning predictions on a text-mined knowledge network. BMC Bioinform., 20.","DOI":"10.1186\/s12859-019-3297-0"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1463\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:26:16Z","timestamp":1760106376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/16\/8\/1463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,11]]},"references-count":119,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,4]]}},"alternative-id":["cancers16081463"],"URL":"https:\/\/doi.org\/10.3390\/cancers16081463","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4,11]]}}}